- Samsung Biologics has agreed to acquire GSK’s Human Genome Sciences manufacturing site in Rockville, Maryland, securing its first U.S.-based manufacturing facility.
- The $280 million transaction adds 60,000 litres of drug substance capacity and supports Samsung Biologics’ CDMO and contract manufacturing services for clinical and commercial biologics.
Samsung Biologics has announced that its wholly owned U.S. subsidiary has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing the company’s first U.S.-based manufacturing site. The move expands Samsung Biologics’ global manufacturing footprint and reinforces its long-term commitment to the U.S. biopharmaceutical market.
The Rockville, Maryland facility comprises two cGMP manufacturing plants with a combined 60,000 litres of drug substance capacity, supporting both clinical and commercial production at small and large scale. Existing products will continue to be manufactured at the site, with Samsung Biologics planning further investments to expand capacity and upgrade technology to support a more resilient U.S. supply chain.
Under the terms of the agreement, which is expected to close towards the end of the first quarter of 2026, Samsung Biologics will acquire the Rockville assets for $280 million. More than 500 employees will be retained to ensure operational continuity, with the facility integrated into Samsung Biologics’ global network to offer clients flexible, multi-site contract manufacturing options across the U.S. and Korea.
“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S.”
John Rim, Chief Executive Officer and President of Samsung Biologics
Samsung Biologics said the acquisition complements its existing capacity of 785,000 litres across five plants and supports its diversified CDMO portfolio, which includes monoclonal antibodies, antibody-drug conjugates, mRNA, organoid-based services, and next-generation therapies.
